Enzo Biochem's Q3 Revenues Drop 13 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Enzo Biochem reported after the close of the market Monday that its third-quarter revenues fell 13 percent year over year as sales from its clinical lab services and products both declined.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.